Results 161 to 170 of about 8,855 (217)

Somatostatin Analogs Inhibit Somatostatin Release*

Endocrinology, 1979
To determine if, like insulin, somatostatin inhibits its own secretion from the pancreas, nonimmunoreactive analogs of somatostatin were perfused in an isolated dog pancreaticoduodenal preparation using a nonrecirculating system. [D-Trp8-D-Cys14]somatostatin, at a concentration of 200 ng/ml, blocked the response of somatostatin-like immunoreactivity ...
E, Ipp, J, Rivier, R E, Dobbs, M, Brown, W, Vale, R H, Unger   +5 more
openaire   +2 more sources

Somatostatin and its Analogs

Current Drug Targets, 2016
Somatostatin (SST) is a cyclic hormone-release inhibitory peptide that has high binding affinity to all of its five SST receptors (SSTRs). SST negatively regulates cell proliferation and the release of multiple hormones via activation of its cognate receptors.
Lichun, Sun, David H, Coy
openaire   +2 more sources

Use of Somatostatin and Somatostatin Analogs in a Patient with a Glucagonoma

The Journal of Clinical Endocrinology & Metabolism, 1981
The effects of somatostatin (SRIF) and, for the first time in man, three of its analogs were studied in a patient with a glucagonoma. Circulating levels of glucagon were greater than 50 ng/ml (normal,
C R, Kahn, S J, Bhathena, L, Recant, J, Rivier   +3 more
openaire   +2 more sources

Somatostatin-28, somatostatin-14 and somatostatin analogs: Effects on thermoregulation

Brain Research, 1981
Somatostatins, somatostatin-14, somatostatin-28, and desAA [D-Trp8]-somatostatin, with differential potencies, act in the brain to reverse chemical-induced hypothermia and to produce hyperthermia. Somatostatins are more potent and loger acting than prostaglandin E2 in producing hyperthermia.
M, Brown, N, Ling, J, Rivier
openaire   +2 more sources

Somatostatin Analogs in the Treatment of Acromegaly

Endocrinology and Metabolism Clinics of North America, 1992
Medical therapy of acromegaly with the somatostatin analog octreotide is very successful. Both clinical symptomatology and hormonal hypersecretion by the growth hormone-secreting pituitary adenomas are controlled, and peripheral IGF-I levels also return to near normal levels. Tumor shrinkage is observed in most patients.
S W, Lamberts, J C, Reubi, E P, Krenning
openaire   +2 more sources

Antiproliferative Effect of Somatostatin and Analogs

Chemotherapy, 2001
Over the past decade, antiproliferative effects of somatostatin and analogs have been reported in many somatostatin receptor-positive normal and tumor cell types. Regarding the molecular mechanisms involved, somatostatin or analogs mediate their action through both indirect and direct effects.
C, Bousquet, E, Puente, L, Buscail, N, Vaysse, C, Susini   +4 more
openaire   +2 more sources

Clinical Applications of Somatostatin Analogs

1985
It has often been shown that tetradecapeptide somatostatin (S-14), discovered in 1973 by Brazeau et al. (1), is effective in the treatment of acromegaly, as adjunct to insulin therapy of type I diabetes, in stopping gastrointestinal bleeding, in treatment of carcinoid syndrome, etc.
P, Marbach, M, Neufeld, J, Pless
openaire   +2 more sources

Clinical applications of somatostatin analogs

Trends in Endocrinology & Metabolism, 1990
The somatostatin analog Sandostatin is successfully used in the treatment of metastatic endocrine pancreatic tumors, carcinoids, and acromegaly. In addition, somatostatin receptors are also present on other tumors in man, therefore making it possible to demonstrate these tumors by the administration of (123)I-coupled to a somatostatin analog.
S W, Lamberts, E P, Krenning, J G, Klijn, J C, Reubi   +3 more
openaire   +2 more sources

Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

Current Molecular Medicine, 2013
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity binding to five different G proteincoupled receptors (GPCRs), named sst1-5.
Ruscica M, ARVIGO, MARICA, Steffani L, FERONE, DIEGO, Magni P.   +4 more
openaire   +4 more sources

Somatostatin: Analogs with Selected Biological Activities

Science, 1976
[D-Cys 14 ]-Somatostatin is the first analog of somatostatin found to be more potent in inhibiting glucagon and growth hormone secretion than it is in inhibiting insulin secretion. [D-Trp 8 ]-Somatostatin is eight to ten times more potent than somatostatin in inhibiting insulin, glucagon, and
M, Brown, J, Rivier, W, Vale
openaire   +3 more sources